Chronic Myeloid Leukemia (BCR-ABL1) · Asciminib (STAMP) for CML-CP 3L+ post-multi-TKI failure

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`REG-ASCIMINIB-CML`

ID	`IND-CML-3L-ASCIMINIB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-CML`
Sources	`SRC-ASCEMBL-REA-2021` `SRC-ELN-CML-2020` `SRC-NCCN-MPN-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ for CML-CP post-multi-TKI failure. Mechanism distinct (allosteric) → minimal cross-resistance. Ukraine access barrier dominant.

Used By

Algorithms

ALGO-CML-2L - ALGO-CML-2L